Related Experiment Video
Updated: Apr 18, 2026
Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
Published on: March 1, 2024
Diagnosis of Pneumocystis pneumonia: evaluation of four serologic biomarkers
Abstract:
The diagnosis of Pneumocystis pneumonia (PCP) relies on microscopic visualization of Pneumocystis jirovecii organisms or DNA detection in pulmonary specimens. This study aimed to assess the usefulness of (1-3)-β-d-glucan (BG), Krebs von den Lungen-6 antigen (KL-6), lactate dehydrogenase (LDH) and S-adenosyl methionine (SAM) as serologic biomarkers in the diagnosis of PCP. Serum levels of BG, KL-6, LDH and SAM were investigated in 145 Portuguese patients, 50 patients from the Netherlands, 25 Spanish patients and 40 Portuguese blood donors. Data on clinical presentation, chest imaging and gasometry tests were available. PCP cases were confirmed by microscopy and PCR techniques. A cost-effectiveness analysis was performed. BG was found to be the most reliable serologic biomarker for PCP diagnosis, followed by KL-6, LDH and SAM. The BG/KL-6 combination test was the most accurate serologic approach for PCP diagnosis, with 94.3% sensitivity and 89.6% specificity. Although less sensitive/specific than the reference standard classic methods based on bronchoalveolar lavage followed by microscopic or molecular detection of P. jirovecii organisms, the BG/KL-6 test may provide a less onerous procedure for PCP diagnosis, as it uses a minimally invasive and inexpensive specimen (blood), which may be also a major benefit for the patient's care. The BG/KL-6 combination test should be interpreted within the clinical context, and it may be used as a preliminary screening test in patients with primary suspicion of PCP, or as an alternative diagnostic procedure in patients with respiratory failure or in children, avoiding the associated risk of complications by the use of bronchoscopy.
Insights
The BG/KL-6 combination blood test shows high accuracy for diagnosing Pneumocystis pneumonia (PCP), offering a less invasive alternative to traditional methods. This approach aids in early detection and patient care, especially for high-risk individuals.
Area of Science:
- Medical diagnostics
- Clinical immunology
- Infectious diseases
Background:
- Pneumocystis pneumonia (PCP) diagnosis traditionally relies on invasive methods like bronchoalveolar lavage.
- Microscopic visualization or DNA detection of Pneumocystis jirovecii in pulmonary specimens are standard diagnostic procedures.
- There is a need for less invasive and potentially more accessible diagnostic markers for PCP.
Purpose of the Study:
- To evaluate the diagnostic utility of serum biomarkers (1-3)-β-d-glucan (BG), KL-6, LDH, and SAM for Pneumocystis pneumonia (PCP).
- To assess the accuracy and cost-effectiveness of these biomarkers, individually and in combination, for PCP diagnosis.
- To determine if serologic biomarkers can serve as a viable alternative or complementary diagnostic tool for PCP.
Main Methods:
- Serum samples from patients with suspected PCP and healthy controls were analyzed for BG, KL-6, LDH, and SAM levels.
- Clinical data, chest imaging, and gasometry results were collected and correlated with biomarker levels.
- PCP diagnosis was confirmed using standard microscopy and PCR on pulmonary specimens.
- A cost-effectiveness analysis was conducted for the evaluated biomarkers.
Main Results:
- Serum (1-3)-β-d-glucan (BG) emerged as the most reliable single biomarker for PCP diagnosis, followed by KL-6, LDH, and SAM.
- The combination of BG and KL-6 demonstrated the highest diagnostic accuracy, achieving 94.3% sensitivity and 89.6% specificity.
- While less sensitive/specific than reference methods, the BG/KL-6 test utilizes minimally invasive blood samples, enhancing patient care and potentially reducing procedural risks.
Conclusions:
- The BG/KL-6 combination test is a highly accurate serologic approach for diagnosing PCP.
- This minimally invasive blood test offers a valuable, less onerous alternative to traditional diagnostic methods, particularly beneficial for high-risk patients.
- The BG/KL-6 test can serve as a preliminary screening tool or an alternative diagnostic procedure, especially in cases of respiratory failure or in pediatric patients, avoiding bronchoscopy risks.
Related Concept Videos
01:30Pneumonia III: Complications and Assessment
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:26Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:29Pneumonia II: Pathophysiology